Weycker D, Hanau A, Hatfield M, Wu H, Sharma A, Bensink ME, et al. Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis. J Med Econ. 2020;23(2):184–92.
Article
Google Scholar
Moulis G, Comont T, Adoue D. New insights into the epidemiology of immune thrombocytopenia in adult patients: impact for clinical practice. Rev Med Interne. 2021;42(1):11–5.
Article
CAS
Google Scholar
Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124(22):3308–15.
Article
CAS
Google Scholar
Piel-Julian ML, Mahevas M, Germain J, Languille L, Comont T, Lapeyre-Mestre M, et al. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. J Thromb Haemost. 2018;16(9):1830–42.
Article
Google Scholar
Frederiksen H, Maegbaek ML, Norgaard M. Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2014;166(2):260–7.
Article
Google Scholar
Doobaree IU, Nandigam R, Bennett D, Newland A, Provan D. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Eur J Haematol. 2016;97(4):321–30.
Article
Google Scholar
Rodeghiero F. ITP and thrombosis: an intriguing association. Blood Adv. 2017;1(24):2280.
Article
CAS
Google Scholar
Swan D, Newland A, Rodeghiero F, Thachil J. Thrombosis in immune thrombocytopenia: current status and future perspectives. Br J Haematol. 2021;194(5):822–34.
Article
CAS
Google Scholar
Ruggeri M, Tosetto A, Palandri F, Polverelli N, Mazzucconi MG, Santoro C, et al. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. J Thromb Haemost. 2014;12(8):1266–73.
Article
CAS
Google Scholar
Cooper N, Kruse A, Kruse C, Watson S, Morgan M, Provan D, et al. Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): impact of ITP on health-related quality of life. Am J Hematol. 2021;96(2):199–207.
Article
Google Scholar
Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–817.
Article
Google Scholar
Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–66.
Article
CAS
Google Scholar
Audia S, Mahevas M, Nivet M, Ouandji S, Ciudad M, Bonnotte B. Immune thrombocytopenia: recent advances in pathogenesis and treatments. Hemasphere. 2021;5(6): e574.
Article
CAS
Google Scholar
Cooper N, Ghanima W. Immune thrombocytopenia. N Engl J Med. 2019;381(10):945–55.
Article
Google Scholar
Liu XG, Ma SH, Sun JZ, Ren J, Shi Y, Sun L, et al. High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fcgamma receptors on monocytes in patients with primary immune thrombocytopenia. Blood. 2011;117(6):2061–9.
Article
CAS
Google Scholar
Audia S, Santegoets K, Laarhoven AG, Vidarsson G, Facy O, Ortega-Deballon P, et al. Fcgamma receptor expression on splenic macrophages in adult immune thrombocytopenia. Clin Exp Immunol. 2017;188(2):275–82.
Article
CAS
Google Scholar
Najaoui A, Bakchoul T, Stoy J, Bein G, Rummel MJ, Santoso S, et al. Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). Eur J Haematol. 2012;88(2):167–74.
Article
CAS
Google Scholar
Cheloff AZ, Kuter DJ, Al-Samkari H. Serum complement levels in immune thrombocytopenia: characterization and relation to clinical features. Res Pract Thromb Haemost. 2020;4(5):807–12.
Article
CAS
Google Scholar
Goette NP, Glembotsky AC, Lev PR, Grodzielski M, Contrufo G, Pierdominici MS, et al. Platelet apoptosis in adult immune thrombocytopenia: insights into the mechanism of damage triggered by auto-antibodies. PLoS ONE. 2016;11(8): e0160563.
Article
Google Scholar
Chen M, Yan R, Zhou K, Li X, Zhang Y, Liu C, et al. Akt-mediated platelet apoptosis and its therapeutic implications in immune thrombocytopenia. Proc Natl Acad Sci USA. 2018;115(45):E10682–91.
Article
CAS
Google Scholar
Catani L, Fagioli ME, Tazzari PL, Ricci F, Curti A, Rovito M, et al. Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol. 2006;34(7):879–87.
Article
CAS
Google Scholar
Catani L, Sollazzo D, Trabanelli S, Curti A, Evangelisti C, Polverelli N, et al. Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia. Ann Hematol. 2013;92(1):67–78.
Article
CAS
Google Scholar
Xu SQ, Wang CY, Zhu XJ, Dong XY, Shi Y, Peng J, et al. Decreased indoleamine 2,3-dioxygenase expression in dendritic cells and role of indoleamine 2,3-dioxygenase-expressing dendritic cells in immune thrombocytopenia. Ann Hematol. 2012;91(10):1623–31.
Article
CAS
Google Scholar
Saito A, Yokohama A, Osaki Y, Ogawa Y, Nakahashi H, Toyama K, et al. Circulating plasmacytoid dendritic cells in patients with primary and Helicobacter pylori-associated immune thrombocytopenia. Eur J Haematol. 2012;88(4):340–9.
Article
CAS
Google Scholar
Kuwana M, Okazaki Y, Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J Thromb Haemost. 2009;7(2):322–9.
Article
CAS
Google Scholar
Asahi A, Nishimoto T, Okazaki Y, Suzuki H, Masaoka T, Kawakami Y, et al. Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. J Clin Invest. 2008;118(8):2939–49.
CAS
Google Scholar
Feng Q, Xu M, Yu YY, Hou Y, Mi X, Sun YX, et al. High-dose dexamethasone or all-trans-retinoic acid restores the balance of macrophages towards M2 in immune thrombocytopenia. J Thromb Haemost. 2017;15(9):1845–58.
Article
CAS
Google Scholar
Zhao Y, Xu P, Guo L, Wang H, Min Y, Feng Q, et al. Tumor necrosis factor-alpha blockade corrects monocyte/macrophage imbalance in primary immune thrombocytopenia. Thromb Haemost. 2021;121(6):767–81.
Article
Google Scholar
Zhang J, Ma D, Zhu X, Qu X, Ji C, Hou M. Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura. Haematologica. 2009;94(9):1326–9.
Article
CAS
Google Scholar
Hu Y, Li H, Zhang L, Shan B, Xu X, Li H, et al. Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia. Hum Immunol. 2012;73(6):629–35.
Article
CAS
Google Scholar
Semple JW, Milev Y, Cosgrave D, Mody M, Hornstein A, Blanchette V, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood. 1996;87(10):4245–54.
Article
CAS
Google Scholar
Olsson B, Andersson PO, Jacobsson S, Carlsson L, Wadenvik H. Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura. Thromb Haemost. 2005;93(1):139–44.
Article
CAS
Google Scholar
Fogarty PF, Rick ME, Zeng W, Risitano AM, Dunbar CE, Bussel JB. T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy. Clin Exp Immunol. 2003;133(3):461–6.
Article
CAS
Google Scholar
Xie J, Cui D, Liu Y, Jin J, Tong H, Wang L, et al. Changes in follicular helper T cells in idiopathic thrombocytopenic purpura patients. Int J Biol Sci. 2015;11(2):220–9.
Article
CAS
Google Scholar
Audia S, Rossato M, Santegoets K, Spijkers S, Wichers C, Bekker C, et al. Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia. Blood. 2014;124(18):2858–66.
Article
CAS
Google Scholar
Liu B, Zhao H, Poon MC, Han Z, Gu D, Xu M, et al. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol. 2007;78(2):139–43.
CAS
Google Scholar
Yu J, Heck S, Patel V, Levan J, Yu Y, Bussel JB, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood. 2008;112(4):1325–8.
Article
CAS
Google Scholar
Stasi R, Cooper N, Del Poeta G, Stipa E, Laura Evangelista M, Abruzzese E, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008;112(4):1147–50.
Article
CAS
Google Scholar
Audia S, Samson M, Guy J, Janikashvili N, Fraszczak J, Trad M, et al. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood. 2011;118(16):4394–400.
Article
CAS
Google Scholar
Yu TS, Wang HY, Zhao YJ, Yu YF, Hou Y, Liu S, et al. Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia. Blood Adv. 2021;5(20):4087–101.
Article
CAS
Google Scholar
Mahevas M, Patin P, Huetz F, Descatoire M, Cagnard N, Bole-Feysot C, et al. B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Investig. 2013;123(1):432–42.
Article
CAS
Google Scholar
Li X, Zhong H, Bao W, Boulad N, Evangelista J, Haider MA, et al. Defective regulatory B-cell compartment in patients with immune thrombocytopenia. Blood. 2012;120(16):3318–25.
Article
CAS
Google Scholar
Hirokawa M, Fujishima N, Togashi M, Saga A, Omokawa A, Saga T, et al. High-throughput sequencing of IgG B-cell receptors reveals frequent usage of the rearranged IGHV4-28/IGHJ4 gene in primary immune thrombocytopenia. Sci Rep. 2019;9(1):8645.
Article
Google Scholar
Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123–4.
Article
CAS
Google Scholar
Zhao C, Li X, Zhang F, Wang L, Peng J, Hou M. Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. Haematologica. 2008;93(9):1428–30.
Article
Google Scholar
Zhou H, Qiu JH, Wang T, Yu YY, Liu XN, Li X, et al. Interleukin 27 inhibits cytotoxic T-lymphocyte-mediated platelet destruction in primary immune thrombocytopenia. Blood. 2014;124(22):3316–9.
Article
CAS
Google Scholar
Audia S, Samson M, Mahevas M, Ferrand C, Trad M, Ciudad M, et al. Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. Blood. 2013;122(14):2477–86.
Article
CAS
Google Scholar
Li J, van der Wal DE, Zhu G, Xu M, Yougbare I, Ma L, et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun. 2015;6:7737.
Article
CAS
Google Scholar
Qiu J, Liu X, Li X, Zhang X, Han P, Zhou H, et al. CD8(+) T cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia. Sci Rep. 2016;6:27445.
Article
CAS
Google Scholar
Zheng SS, Ahmadi Z, Leung HHL, Wong R, Yan F, Perdomo JS, et al. Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia. Haematologica. 2022;107(9):2195–205.
Article
CAS
Google Scholar
Deppermann C, Kratofil RM, Peiseler M, David BA, Zindel J, Castanheira F et al. Macrophage galactose lectin is critical for Kupffer cells to clear aged platelets. J Exp Med. 2020;217(4).
Jiang Y, Tang Y, Hoover C, Kondo Y, Huang D, Restagno D, et al. Kupffer cell receptor CLEC4F is important for the destruction of desialylated platelets in mice. Cell Death Differ. 2021;28(11):3009–21.
Article
CAS
Google Scholar
Heyns Adu P, Badenhorst PN, Lotter MG, Pieters H, Wessels P, Kotze HF. Platelet turnover and kinetics in immune thrombocytopenic purpura: results with autologous 111In-labeled platelets and homologous 51Cr-labeled platelets differ. Blood. 1986;67(1):86–92.
Article
Google Scholar
Sakuragi M, Hayashi S, Maruyama M, Kabutomori O, Kiyokawa T, Nagamine K, et al. Clinical significance of IPF% or RP% measurement in distinguishing primary immune thrombocytopenia from aplastic thrombocytopenic disorders. Int J Hematol. 2015;101(4):369–75.
Article
CAS
Google Scholar
Cybulska A, Meintker L, Ringwald J, Krause SW. Measurements of immature platelets with haematology analysers are of limited value to separate immune thrombocytopenia from bone marrow failure. Br J Haematol. 2017;177(4):612–9.
Article
CAS
Google Scholar
Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102(3):887–95.
Article
CAS
Google Scholar
McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103(4):1364–9.
Article
CAS
Google Scholar
Yang L, Wang L, Zhao CH, Zhu XJ, Hou Y, Jun P, et al. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. Blood. 2010;116(20):4307–16.
Article
CAS
Google Scholar
Li S, Wang L, Zhao C, Li L, Peng J, Hou M. CD8+ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura. Br J Haematol. 2007;139(4):605–11.
Article
Google Scholar
Olsson B, Ridell B, Carlsson L, Jacobsson S, Wadenvik H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood. 2008;112(4):1078–84.
Article
CAS
Google Scholar
Wang M, Feng R, Zhang JM, Xu LL, Feng FE, Wang CC, et al. Dysregulated megakaryocyte distribution associated with nestin(+) mesenchymal stem cells in immune thrombocytopenia. Blood Adv. 2019;3(9):1416–28.
Article
CAS
Google Scholar
Li H, Guan Y, Sun B, Dou X, Liu X, Xue F, et al. Role of bone marrow-derived mesenchymal stem cell defects in CD8(+) CD28(-) suppressor T-lymphocyte induction in patients with immune thrombocytopenia and associated mechanisms. Br J Haematol. 2020;191(5):852–62.
Article
CAS
Google Scholar
Kong Y, Cao XN, Zhang XH, Shi MM, Lai YY, Wang Y, et al. Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients. Blood. 2018;131(11):1219–33.
Article
CAS
Google Scholar
Wang Q, Li J, Yu TS, Liu Y, Li K, Liu S, et al. Disrupted balance of CD4(+) T-cell subsets in bone marrow of patients with primary immune thrombocytopenia. Int J Biol Sci. 2019;15(13):2798–814.
Article
Google Scholar
Kosugi S, Kurata Y, Tomiyama Y, Tahara T, Kato T, Tadokoro S, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol. 1996;93(3):704–6.
Article
CAS
Google Scholar
Arnold DM, Nazy I, Clare R, Jaffer AM, Aubie B, Li N, et al. Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. Blood Adv. 2017;1(25):2414–20.
Article
Google Scholar
Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood. 2020;135(7):472–90.
Article
Google Scholar
Liu XG, Bai XC, Chen FP, Cheng YF, Dai KS, Fang MY, et al. Chinese guidelines for treatment of adult primary immune thrombocytopenia. Int J Hematol. 2018;107(6):615–23.
Article
Google Scholar
Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020). Zhonghua Xue Ye Xue Za Zhi. 2020;41(8):617–23.
Google Scholar
Kuendgen A, Matsuda A, Germing U. Differences in epidemiology of MDS between Western and Eastern countries: ethnic differences or environmental influence? Leuk Res. 2007;31(1):103–4.
Article
Google Scholar
Red Blood Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of aplastic anemia. Zhonghua Xue Ye Xue Za Zhi. 2017;38(1):1–5.
Google Scholar
Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1–15.
Article
Google Scholar
Porcelijn L, Huiskes E, Oldert G, Schipperus M, Zwaginga JJ, de Haas M. Detection of platelet autoantibodies to identify immune thrombocytopenia: state of the art. Br J Haematol. 2018;182(3):423–6.
Article
Google Scholar
Al-Samkari H, Rosovsky RP, Karp Leaf RS, Smith DB, Goodarzi K, Fogerty AE, et al. A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. Blood Adv. 2020;4(1):9–18.
Article
CAS
Google Scholar
Vrbensky JR, Moore JE, Arnold DM, Smith JW, Kelton JG, Nazy I. The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: a systematic review and meta-analysis of a diagnostic test. J Thromb Haemost. 2019;17(5):787–94.
Article
Google Scholar
Ogata K, Tamura H. Thrombopoietin and myelodysplastic syndromes. Int J Hematol. 2000;72(2):173–7.
CAS
Google Scholar
Johnson B, Doak R, Allsup D, Astwood E, Evans G, Grimley C, et al. A comprehensive targeted next-generation sequencing panel for genetic diagnosis of patients with suspected inherited thrombocytopenia. Res Pract Thromb Haemost. 2018;2(4):640–52.
Article
CAS
Google Scholar
Wang Y, Yu T, Dong Q, Liu S, Yu Y, Zhao HY, et al. Clonal hematopoiesis in primary immune thrombocytopenia. Blood Cancer J. 2022;12(3):40.
Article
CAS
Google Scholar
Jaime-Perez JC, Aguilar-Calderon P, Jimenez-Castillo RA, Ramos-Davila EM, Salazar-Cavazos L, Gomez-Almaguer D. Treatment outcomes and chronicity predictors for primary immune thrombocytopenia: 10-year data from an academic center. Ann Hematol. 2020;99(11):2513–20.
Article
CAS
Google Scholar
Giordano P, Urbano F, Lassandro G, Bianchi FP, Tolva A, Saracco P, et al. Role of antithyroid autoimmunity as a predictive biomarker of chronic immune thrombocytopenia. Pediatr Blood Cancer. 2019;66(1): e27452.
Article
Google Scholar
Heitink-Polle KM, Nijsten J, Boonacker CW, de Haas M, Bruin MC. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis. Blood. 2014;124(22):3295–307.
Article
CAS
Google Scholar
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–93.
Article
CAS
Google Scholar
Vianelli N, Auteri G, Buccisano F, Carrai V, Baldacci E, Clissa C, et al. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives. Ann Hematol. 2022;101(5):963–78.
Article
Google Scholar
Rodeghiero F, Michel M, Gernsheimer T, Ruggeri M, Blanchette V, Bussel JB, et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood. 2013;121(14):2596–606.
Article
CAS
Google Scholar
Hato T, Shimada N, Kurata Y, Kuwana M, Fujimura K, Kashiwagi H, et al. Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP: a nationwide study in Japan. Blood Adv. 2020;4(8):1648–55.
Article
Google Scholar
Neunert C, Noroozi N, Norman G, Buchanan GR, Goy J, Nazi I, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2015;13(3):457–64.
Article
CAS
Google Scholar
Wang M, Liu W, Xu Y, Wang H, Guo X, Ding X, et al. Predicting bleeding risk in a Chinese immune thrombocytopenia (ITP) population: development and assessment of a new predictive nomogram. Sci Rep. 2020;10(1):15337.
Article
Google Scholar
Sokal A, de Nadai T, Maquet J, Comont T, Limal N, Michel M, et al. Primary immune thrombocytopenia in very elderly patients: particularities in presentation and management: results from the prospective CARMEN-France Registry. Br J Haematol. 2022;196(5):1262–70.
Article
CAS
Google Scholar
Altomare I, Cetin K, Wetten S, Wasser JS. Rate of bleeding-related episodes in adult patients with primary immune thrombocytopenia: a retrospective cohort study using a large administrative medical claims database in the US. Clin Epidemiol. 2016;8:231–9.
Google Scholar
Chong S, Zhao P, Huang RB, Zhou H, Zhang JN, Hou M, et al. Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study. Blood Adv. 2022;6(14):4320–9.
Article
Google Scholar
Cooper N, Morrison MA, Vladescu C, Hart ACJ, Paul D, Malik A, et al. Identification of occult cerebral microbleeds in adults with immune thrombocytopenia. Blood. 2020;136(25):2875–80.
Article
Google Scholar
Frelinger AL 3rd, Grace RF, Gerrits AJ, Carmichael SL, Forde EE, Michelson AD. Platelet function in ITP, independent of platelet count, is consistent over time and is associated with both current and subsequent bleeding severity. Thromb Haemost. 2018;118(1):143–51.
Article
Google Scholar
Frelinger AL 3rd, Grace RF, Gerrits AJ, Berny-Lang MA, Brown T, Carmichael SL, et al. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood. 2015;126(7):873–9.
Article
CAS
Google Scholar
Boulware R, Refaai MA. Why do patients with immune thrombocytopenia (ITP) experience lower bleeding events despite thrombocytopenia? Thromb Res. 2020;187:154–8.
Article
CAS
Google Scholar
Frederiksen H, Ghanima W. Response of first line treatment with corticosteroids in a population-based cohort of adults with primary immune thrombocytopenia. Eur J Intern Med. 2017;37:e23–5.
Article
Google Scholar
Nakazaki K, Hosoi M, Hangaishi A, Ichikawa M, Nannya Y, Kurokawa M. Comparison between pulsed high-dose dexamethasone and daily corticosteroid therapy for adult primary immune thrombocytopenia: a retrospective study. Intern Med. 2012;51(8):859–63.
Article
CAS
Google Scholar
Matschke J, Muller-Beissenhirtz H, Novotny J, Vester I, Hertenstein B, Eisele L, et al. A randomized trial of daily prednisone versus pulsed dexamethasone in treatment-naive adult patients with immune thrombocytopenia: EIS 2002 study. Acta Haematol. 2016;136(2):101–7.
Article
CAS
Google Scholar
Sakamoto K, Nakasone H, Tsurumi S, Sasaki K, Mitani K, Kida M, et al. Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study Group. J Thromb Thrombolysis. 2014;37(3):279–86.
Article
CAS
Google Scholar
Wei Y, Ji XB, Wang YW, Wang JX, Yang EQ, Wang ZC, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016;127(3):296–302.
Article
CAS
Google Scholar
Mithoowani S, Gregory-Miller K, Goy J, Miller MC, Wang G, Noroozi N, et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2016;3(10):e489–96.
Article
Google Scholar
Palandri F, Santoro C, Carpenedo M, Cantoni S, Barcellini W, Carli G, et al. Management of elderly patients with immune thrombocytopenia: real-world evidence from 451 patients older than 60 years. Thromb Res. 2020;185:88–95.
Article
CAS
Google Scholar
Qin YH, Zhou TB, Su LN, Lei FY, Zhao YJ, Huang WF. The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic thrombocytopenic purpura: a meta-analysis of 13 randomized controlled trials. Blood Coagul Fibrinolysis. 2010;21(8):713–21.
Article
CAS
Google Scholar
Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica. 2005;90(6):829–32.
Google Scholar
Zhou Z, Qiao Z, Li H, Luo N, Zhang X, Xue F, et al. Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: results of a prospective study including 167 cases. Autoimmunity. 2016;49(1):50–7.
Article
CAS
Google Scholar
Peng J, Ma SH, Liu J, Hou Y, Liu XM, Niu T, et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost. 2014;12(4):497–504.
Article
CAS
Google Scholar
Rogier T, Samson M, Mourey G, Falvo N, Magy-Bertrand N, Ouandji S et al. Antiplatelet antibodies do not predict the response to intravenous immunoglobulins during immune thrombocytopenia. J Clin Med. 2020;9(6).
Newman GC, Novoa MV, Fodero EM, Lesser ML, Woloski BM, Bussel JB. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol. 2001;112(4):1076–8.
Article
CAS
Google Scholar
Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115(14):2755–62.
Article
CAS
Google Scholar
Gudbrandsdottir S, Birgens HS, Frederiksen H, Jensen BA, Jensen MK, Kjeldsen L, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. 2013;121(11):1976–81.
Article
CAS
Google Scholar
Wang J, Li Y, Wang C, Zhang Y, Gao C, Lang H, et al. Efficacy and safety of the combination treatment of rituximab and dexamethasone for adults with primary immune thrombocytopenia (ITP): a meta-analysis. Biomed Res Int. 2018;2018:1316096.
Article
Google Scholar
Gomez-Almaguer D, Herrera-Rojas MA, Jaime-Perez JC, Gomez-De Leon A, Cantu-Rodriguez OG, Gutierrez-Aguirre CH, et al. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood. 2014;123(25):3906–8.
Article
CAS
Google Scholar
Zhang L, Zhang M, Du X, Cheng Y, Cheng G. Safety and efficacy of eltrombopag plus pulsed dexamethasone as first-line therapy for immune thrombocytopenia. Br J Haematol. 2020;189(2):369–78.
Article
CAS
Google Scholar
Gomez-Almaguer D, Colunga-Pedraza PR, Gomez-De Leon A, Gutierrez-Aguirre CH, Cantu-Rodriguez OG, Jaime-Perez JC. Eltrombopag, low-dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopaenia. Br J Haematol. 2019;184(2):288–90.
Article
Google Scholar
Colunga-Pedraza PRR, Bustillos Muñoz M, De La Garza F, Gomez-De Leon A, Coronado-Alejandro EU, Gomez Gomez ET, et al. Romiplostim, low-dose rituximab and high-dose dexamethasone combination in newly diagnosed immune thrombocytopenia: another “total therapy” pilot study. Blood. 2021;138(Supplement 1):1014.
Article
Google Scholar
Yu Y, Wang M, Hou Y, Qin P, Zeng Q, Yu W, et al. High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: a prospective, multicenter, randomized trial. Am J Hematol. 2020;95(12):1542–52.
Article
CAS
Google Scholar
Bradbury CA, Pell J, Hill Q, Bagot C, Cooper N, Ingram J, et al. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. N Engl J Med. 2021;385(10):885–95.
Article
CAS
Google Scholar
Huang QS, Liu Y, Wang JB, Peng J, Hou M, Liu H, et al. All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Haematol. 2021;8(10):e688–99.
Article
Google Scholar
Revilla N, Corral J, Minano A, Mingot-Castellano ME, Campos RM, Velasco F, et al. Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content. Platelets. 2019;30(6):743–51.
Article
CAS
Google Scholar
Sun L, Wang J, Shao L, Yuan C, Zhao H, Li D, et al. Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. Lancet Haematol. 2021;8(4):e289–98.
Article
Google Scholar
Roumier M, Le Burel S, Audia S, Chauchet A, Gousseff M, Hamidou M, et al. High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia. Am J Hematol. 2021;96(2):E43–6.
Article
CAS
Google Scholar
Moulis G, Germain J, Comont T, Brun N, Dingremont C, Castel B, et al. Newly diagnosed immune thrombocytopenia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort. Am J Hematol. 2017;92(6):493–500.
Article
CAS
Google Scholar
Birocchi S, Podda GM, Manzoni M, Casazza G, Cattaneo M. Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review. Platelets. 2021;32(2):216–26.
Article
CAS
Google Scholar
Al-Samkari H, Kuter DJ. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. Am J Hematol. 2018;93(12):1501–8.
Article
CAS
Google Scholar
Makar RS, Zhukov OS, Sahud MA, Kuter DJ. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists. Am J Hematol. 2013;88(12):1041–4.
Article
CAS
Google Scholar
Wang L, Gao Z, Chen XP, Zhang HY, Yang N, Wang FY, et al. Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: a systematic review and meta-analysis. Sci Rep. 2016;6:39003.
Article
CAS
Google Scholar
Mei H, Xu M, Yuan G, Zhu F, Guo J, Huang R, et al. A multicentre double-blind, double-dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients. Br J Haematol. 2021;195(5):781–9.
Article
CAS
Google Scholar
Puavilai T, Thadanipon K, Rattanasiri S, Ingsathit A, McEvoy M, Attia J, et al. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis. Br J Haematol. 2020;188(3):450–9.
Article
CAS
Google Scholar
Jurczak W, Chojnowski K, Mayer J, Krawczyk K, Jamieson BD, Tian W, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479–90.
Article
CAS
Google Scholar
Snell Taylor SJ, Nielson CM, Breskin A, Saul B, Yu Y, Alam N, et al. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic immune thrombocytopenia in European clinical practice. Adv Ther. 2021;38(5):2673–88.
Article
CAS
Google Scholar
Wang S, Yang R, Zou P, Hou M, Wu D, Shen Z, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. Int J Hematol. 2012;96(2):222–8.
Article
CAS
Google Scholar
Cai HC, Wang SJ, Fu L, Wang XM, Hou M, Qin P, et al. A prospective study of the efficacy and safety of maintenance therapy with recombinant human thrombopoietin in patients with primary immune thrombocytopenia: a multicenter study. Zhonghua Xue Ye Xue Za Zhi. 2017;38(5):379–83.
CAS
Google Scholar
Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Wojdyla M, et al. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study. Br J Haematol. 2022;197(3):359–66.
Article
CAS
Google Scholar
Gonzalez-Porras JR, Godeau B, Carpenedo M. Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia. Ther Adv Hematol. 2019;10:2040620719837906.
Article
CAS
Google Scholar
Khellaf M, Viallard JF, Hamidou M, Cheze S, Roudot-Thoraval F, Lefrere F, et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 2013;98(6):881–7.
Article
CAS
Google Scholar
Lucchini E, Palandri F, Volpetti S, Vianelli N, Auteri G, Rossi E, et al. Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study. Br J Haematol. 2021;193(2):386–96.
Article
CAS
Google Scholar
Kuter DJ, Newland A, Chong BH, Rodeghiero F, Romero MT, Pabinger I, et al. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. Br J Haematol. 2019;185(3):503–13.
Article
CAS
Google Scholar
Mahevas M, Guillet S, Viallard J-F, Gobert D, Malphettes M, Cheze S, et al. Rate of prolonged response after stopping thrombopoietin-receptor agonists treatment in primary immune thrombocytopenia (ITP): results from a nationwide prospective multicenter interventional study (STOPAGO). Blood. 2021;138(Supplement 1):583.
Article
Google Scholar
Cuker A, Despotovic JM, Grace RF, Kruse C, Lambert MP, Liebman HA, et al. Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: expert consensus based on the RAND/UCLA modified Delphi panel method. Res Pract Thromb Haemost. 2021;5(1):69–80.
Article
CAS
Google Scholar
Tjepkema M, Amini S, Schipperus M. Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022;171: 103581.
Article
Google Scholar
van Dijk WEM, Brandwijk ON, Heitink-Polle KMJ, Schutgens REG, van Galen KPM, Urbanus RT. Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients. Blood Rev. 2021;47: 100774.
Article
Google Scholar
Lucchini E, Zaja F, Bussel J. Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? Haematologica. 2019;104(6):1124–35.
Article
CAS
Google Scholar
Dong Y, Yue M, Hu M. The efficacy and safety of different dosages of rituximab for adults with immune thrombocytopenia: a systematic review and meta-analysis. Biomed Res Int. 2021;2021:9992086.
Article
Google Scholar
Deshayes S, Khellaf M, Zarour A, Layese R, Fain O, Terriou L, et al. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5 years from the French prospective registry ITP-ritux. Am J Hematol. 2019;94(12):1314–24.
Article
CAS
Google Scholar
Feng R, Liu X, Zhao Y, Zhu Y, Peng J, Hou M, et al. GPIIb/IIIa autoantibody predicts better rituximab response in ITP. Br J Haematol. 2018;182(2):305–7.
Article
Google Scholar
Wang YM, Yu YF, Liu Y, Liu S, Hou M, Liu XG. The association between antinuclear antibody and response to rituximab treatment in adult patients with primary immune thrombocytopenia. Hematology. 2020;25(1):139–44.
Article
CAS
Google Scholar
Bussel J, Arnold DM, Grossbard E, Mayer J, Trelinski J, Homenda W, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921–30.
Article
CAS
Google Scholar
Bussel JB, Arnold DM, Boxer MA, Cooper N, Mayer J, Zayed H, et al. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. Am J Hematol. 2019;94(5):546–53.
Article
CAS
Google Scholar
Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: down but not out. Blood. 2018;131(11):1172–82.
Article
CAS
Google Scholar
Mageau A, Terriou L, Ebbo M, Souchaud-Debouverie O, Orvain C, Graveleau J, et al. Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: new insights for an old treatment. Am J Hematol. 2022;97(1):10–7.
Article
CAS
Google Scholar
Finianos A, Mujadzic H, Peluso H, Mujadzic T, Taher A, Abougergi MS. Temporal trends and outcome of splenectomy in adults with immune thrombocytopenia in the USA. Ann Hematol. 2021;100(4):941–52.
Article
Google Scholar
Thai LH, Mahevas M, Roudot-Thoraval F, Limal N, Languille L, Dumas G, et al. Long-term complications of splenectomy in adult immune thrombocytopenia. Medicine (Baltimore). 2016;95(48): e5098.
Article
CAS
Google Scholar
Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood. 2013;121(23):4782–90.
Article
CAS
Google Scholar
Edgren G, Almqvist R, Hartman M, Utter GH. Splenectomy and the risk of sepsis: a population-based cohort study. Ann Surg. 2014;260(6):1081–7.
Article
Google Scholar
Kuter DJ, Efraim M, Mayer J, Trneny M, McDonald V, Bird R, et al. Rilzabrutinib, an Oral BTK Inhibitor, Immune Thrombocytopenia. N Engl J Med. 2022;386(15):1421–31.
Article
CAS
Google Scholar
Robak T, Kazmierczak M, Jarque I, Musteata V, Trelinski J, Cooper N, et al. Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. Blood Adv. 2020;4(17):4136–46.
Article
CAS
Google Scholar
Newland AC, Sanchez-Gonzalez B, Rejto L, Egyed M, Romanyuk N, Godar M, et al. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol. 2020;95(2):178–87.
Article
CAS
Google Scholar
Broome CM, Roth A, Kuter DJ, Scully M, Smith R, Wang J et al. Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia. Blood Adv. 2022.
Zhou H, Hou Y, Liu X, Qiu J, Feng Q, Wang Y, et al. Low-dose decitabine promotes megakaryocyte maturation and platelet production in healthy controls and immune thrombocytopenia. Thromb Haemost. 2015;113(5):1021–34.
Article
Google Scholar
Han P, Hou Y, Zhao Y, Liu Y, Yu T, Sun Y, et al. Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia. Blood. 2021;138(8):674–88.
Article
CAS
Google Scholar
Zhou H, Qin P, Liu Q, Yuan C, Hao Y, Zhang H, et al. A prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia. Am J Hematol. 2019;94(12):1374–81.
Article
CAS
Google Scholar
Mahevas M, Gerfaud-Valentin M, Moulis G, Terriou L, Audia S, Guenin S, et al. Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. Blood. 2016;128(12):1625–30.
Article
CAS
Google Scholar
Zhou H, Xu M, Qin P, Zhang HY, Yuan CL, Zhao HG, et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. Blood. 2015;125(10):1541–7.
Article
CAS
Google Scholar
Feng FE, Feng R, Wang M, Zhang JM, Jiang H, Jiang Q, et al. Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. Lancet Haematol. 2017;4(10):e487–96.
Article
Google Scholar
Wu YJ, Liu H, Zeng QZ, Liu Y, Wang JW, Wang WS, et al. All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. Blood. 2022;139(3):333–42.
Article
CAS
Google Scholar
Khellaf M, Chabrol A, Mahevas M, Roudot-Thoraval F, Limal N, Languille L, et al. Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. Am J Hematol. 2014;89(2):194–8.
Article
CAS
Google Scholar
Kong Z, Qin P, Xiao S, Zhou H, Li H, Yang R, et al. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood. 2017;130(9):1097–103.
Article
CAS
Google Scholar
Michel M, Ruggeri M, Gonzalez-Lopez TJ, Alkindi S, Cheze S, Ghanima W, et al. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. Blood. 2020;136(26):3056–61.
Article
CAS
Google Scholar
Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499–506.
Article
CAS
Google Scholar
Mahevas M, Moulis G, Andres E, Riviere E, Garzaro M, Crickx E, et al. Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. Br J Haematol. 2020;190(4):e224–9.
Article
CAS
Google Scholar
Alharbi MG, Alanazi N, Yousef A, Alanazi N, Alotaibi B, Aljurf M, et al. COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis. Expert Rev Hematol. 2022;15(2):157–66.
Article
CAS
Google Scholar
Pavord S, Thachil J, Hunt BJ, Murphy M, Lowe G, Laffan M, et al. Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol. 2020;189(6):1038–43.
Article
CAS
Google Scholar
Rodeghiero F, Cantoni S, Carli G, Carpenedo M, Carrai V, Chiurazzi F, et al. Practical recommendations for the management of patients with ITP during the COVID-19 pandemic. Mediterr J Hematol Infect Dis. 2021;13(1): e2021032.
Article
Google Scholar
Wichmann D, Sperhake JP, Lutgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020;173(4):268–77.
Article
Google Scholar
Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost. 2020;4(7):1178–91.
Article
CAS
Google Scholar
Lee EJ, Beltrami-Moreira M, Al-Samkari H, Cuker A, DiRaimo J, Gernsheimer T, et al. SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. Blood. 2022;139(10):1564–74.
Article
CAS
Google Scholar
Visser C, Swinkels M, van Werkhoven ED, Croles FN, Noordzij-Nooteboom HS, Eefting M, et al. COVID-19 vaccination in patients with immune thrombocytopenia. Blood Adv. 2022;6(6):1637–44.
Article
CAS
Google Scholar